Sarepta Therapeutics, Inc. (SRPT) Wednesday said that the UK's Medicines & Healthcare products Regulatory Agency (MHRA) has given clearance to continue dosing in the ENVISION Study of its gene therapy Elevidys for the treatment of Duchenne Muscular Dystrophy.
ENVISION is a Phase 3 study of Elevidys in non-ambulatory and older ambulatory individuals with Duchenne.
In the U.S., Elevidys is approved for the treatment of Duchenne Muscular Dystrophy in patients aged 4 and above.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.